Theranica’s Nerivio REN wearable device shows promising results in treatment of migraine in children under 12 years

Theranica, a neuromodulation therapeutics company, announced results from a prospective real-world evidence study evaluating the safety and efficacy of remote electrical neuromodulation (REN) as a treatment for migraine in children ages 6 to 11. The study has been published in Annals of the Child Neurology Society.

Controlled by a smartphone app and self-administered, the Nerivio REN wearable is a complete migraine care treatment that wraps around the upper arm and uses sub-painful Remote Electrical Neuromodulation (REN) to activate nociceptive nerve fibers in the arm. These fibers send signals that trigger a descending pain management mechanism in the brain called conditioned pain modulation (CPM), which turns off migraine pain and associated symptoms without medication. The upper arm is stimulated to start a natural process in the brain to abort or relieve migraine headaches and other associated symptoms. Each treatment lasts 45 minutes and is applied every other day for prevention or at the start of a migraine attack for acute treatment.

The Nerivio REN wearable is the first FDA-cleared, non-drug, easy-to-use treatment for both acute migraine attacks and prevention of migraine with or without aura in adolescents and adults ages 12 and older. The treatment is currently under FDA review to possibly expand the indication to eight years of age and older.

This recently published clinical study, involving 293 children aged 6 to 11, has shown promising results regarding the safety and effectiveness of the Nerivio REN wearable device as a non-pharmacological treatment for migraine.